TRYNGOLZA® becomes the first and only FDA-approved treatment for severe hypertriglyceridemia, reducing both triglyceride levels and the risk of acute pancreatitis.
Ionis Pharmaceuticals has secured a major regulatory milestone with the U.S. Food and Drug Administration’s approval of TRYNGOLZA (olezarsen) as an adjunct to diet for adults with severe hypertriglyceridemia (sHTG), giving patients and physicians a new therapy designed to lower dangerously high triglyceride levels and reduce the risk of acute pancreatitis. The decision significantly broadens the commercial and clinical reach of olezarsen, which had previously been approved for familial chylomicronemia syndrome (FCS), and positions Ionis to launch the drug into a much larger cardiometabolic market. (U.S. Food and Drug Administration)
Under the new label, TRYNGOLZA is indicated for adults with fasting triglyceride levels of 500 mg/dL or higher, a threshold associated with a sharply increased risk of pancreatitis and other complications. The drug is available in 50 mg and 80 mg doses and is self-administered once monthly via an autoinjector, offering a relatively convenient dosing schedule for a chronic condition that has long been difficult to control despite lifestyle changes and conventional lipid-lowering therapies. (U.S. Food and Drug Administration)
The approval marks an important moment not only for patients with severe hypertriglyceridemia, but also for Ionis itself. It is the company’s first independent launch in a prevalent disease, moving the biotech beyond its roots in rare disease and specialized RNA-targeted therapeutics toward a broader commercial footprint in metabolic medicine. The decision also validates a clinical development strategy centered on demonstrating not just triglyceride lowering, but a clinically meaningful reduction in the risk of acute pancreatitis, one of the most feared complications of severe hypertriglyceridemia. (U.S. Food and Drug Administration)
A Serious Condition With Limited Effective Options
Severe hypertriglyceridemia is characterized by extremely elevated triglyceride levels in the blood—typically 500 mg/dL or greater—and is associated with a substantially increased risk of acute pancreatitis, a painful and potentially life-threatening inflammatory condition of the pancreas. While triglycerides are often discussed in the context of cardiovascular health, in the severe range the more immediate clinical concern is pancreatitis, which can cause sudden, severe abdominal pain, recurrent hospitalizations, organ damage, and in some cases death. (U.S. Food and Drug Administration)
Patients with sHTG are usually advised to adopt strict lifestyle interventions, including dietary fat restriction, weight management, regular exercise, diabetes control, and avoidance of alcohol, and many are already taking standard lipid-lowering therapies such as fibrates, omega-3 fatty acids, or statins. Yet for a meaningful subset of patients, these measures do not reliably lower triglycerides enough to reduce pancreatitis risk. That gap has created a longstanding need for therapies capable of delivering more substantial and durable triglyceride control, particularly in patients with very high baseline levels or a prior history of pancreatitis. (U.S. Food and Drug Administration)
Ionis has framed TRYNGOLZA as a response to that unmet need. The company says the approval gives physicians the first FDA-approved therapy for sHTG shown to reduce both triglycerides and acute pancreatitis events, a distinction that is central to how it plans to position the product in the market. The FDA likewise emphasized that previously approved triglyceride-lowering medicines for severe hypertriglyceridemia had not accumulated enough pancreatitis events in clinical trials to establish a reduction in pancreatitis risk, making TRYNGOLZA’s evidence package particularly notable. (U.S. Food and Drug Administration)
Approval Backed by the Phase 3 CORE and CORE2 Trials
The FDA’s decision was based on data from the Phase 3 CORE and CORE2 studies, two randomized, double-blind, placebo-controlled trials that together enrolled 1,061 adults with severe hypertriglyceridemia. Participants in the studies had an average baseline triglyceride level of approximately 1,116 mg/dL, reflecting a population at very high risk of pancreatitis and other complications. The trials evaluated monthly subcutaneous doses of olezarsen on top of background standard-of-care therapy and lifestyle management. (U.S. Food and Drug Administration)
Across the studies, TRYNGOLZA delivered rapid and substantial reductions in fasting triglyceride levels. In one trial, the average placebo-adjusted change from baseline to six months was -63% for the 50 mg dose and -72% for the 80 mg dose. In the second trial, the reductions were -49% for the 50 mg dose and -55% for the 80 mg dose. Ionis has emphasized that these reductions were sustained through 12 months of treatment, supporting the case for ongoing long-term benefit in a chronic disease setting. (U.S. Food and Drug Administration)
The company also highlighted the proportion of patients who reached a clinically meaningful triglyceride threshold. Among patients with both baseline and 12-month data, 86% achieved triglyceride levels below 500 mg/dL, a level generally viewed as important for lowering the risk of pancreatitis. Ionis argues that this threshold-based outcome is especially relevant for clinicians because it reflects not just relative percentage reductions, but the ability to bring patients beneath a recognized danger zone. (Ionis Pharmaceuticals, Inc.)
Reduction in Acute Pancreatitis Is a Key Differentiator
Perhaps the most consequential aspect of the TRYNGOLZA data package is the observed impact on acute pancreatitis events. According to the FDA, the integrated analysis of the two Phase 3 trials showed that the rate of acute pancreatitis was reduced in the pooled TRYNGOLZA group compared with placebo. Ionis has described the reduction as up to 91% in its approval announcement, while earlier topline reporting from the pivotal studies cited an 85% reduction in pancreatitis events overall. The FDA has characterized the approval as the first for a therapy shown to reduce the risk of acute pancreatitis in adults with severe hypertriglyceridemia. (U.S. Food and Drug Administration)
This distinction matters because pancreatitis is not a theoretical long-term risk for many sHTG patients—it is often the event that defines the disease burden. Recurrent pancreatitis attacks can be excruciating, require prolonged hospitalization, and leave lasting pancreatic damage. For the highest-risk patients, especially those with triglycerides of 880 mg/dL or higher or a prior history of pancreatitis, preventing the next episode can be as important as lowering the triglyceride number itself.
Ionis underscored that point by sharing number needed to treat (NNT) analyses from the clinical program. Over one year, the company said the NNT to prevent one episode of acute pancreatitis was 20 in the overall study cohort and four in the subgroup with triglycerides ≥880 mg/dL and a prior history of acute pancreatitis. Those figures suggest that the greatest clinical benefit may be concentrated in patients at the very highest risk, though the broader data support benefit across the severe hypertriglyceridemia spectrum. (Ionis Pharmaceuticals, Inc.)
Safety Profile Appears Manageable, With Monitoring for Liver Enzymes
From a safety perspective, TRYNGOLZA demonstrated what Ionis described as a favorable safety and tolerability profile across the sHTG clinical program. According to the FDA, the most common adverse reactions in patients with severe hypertriglyceridemia were injection-site reactions and elevations in liver enzymes. The agency recommends that healthcare providers consider liver enzyme testing before initiating treatment or increasing the dose, and periodically thereafter when clinically indicated. If persistent liver enzyme elevations occur, dose interruption or dose reduction may be considered. (U.S. Food and Drug Administration)
The FDA also noted that allergic reactions have been reported with TRYNGOLZA, including symptoms such as skin redness, hives, facial swelling, chills, or difficulty breathing. Patients are advised to discontinue the medication and seek medical attention if such reactions occur. (U.S. Food and Drug Administration)
The once-monthly autoinjector format may help support adherence, particularly in a condition where patients often face years of ongoing management and repeated lifestyle counseling. Ionis has said the drug will be available in the U.S. in July, and it plans to support access through its Ionis Every Step program, which will offer patient services including injection training, nutrition information, insurance support, and financial assistance. The company has also pointed patients and providers to TRYNGOLZA.com for additional information about the medicine and support services.
Ionis Positions TRYNGOLZA as a Transformational Product
Brett Monia, Ionis’ chief executive officer, described the approval as a landmark moment for patients who have struggled for years to control dangerously high triglycerides. In the company’s view, TRYNGOLZA represents more than a new lipid-lowering medicine; it is the first therapy in sHTG with the potential to dramatically lower triglycerides while also significantly reducing acute pancreatitis events. Monia also tied the approval to the broader evolution of Ionis as a company, saying it builds on the earlier FCS launch and represents a defining step in bringing the company’s RNA-targeted medicines to a broader patient population. (U.S. Food and Drug Administration)
Outside the company, clinicians and patient advocates have echoed the importance of expanding treatment options in this area. Severe hypertriglyceridemia can be difficult to manage even under specialist care, and many patients remain above the 500 mg/dL threshold despite multiple medications and lifestyle interventions. For those who have already experienced pancreatitis, the condition can create a constant fear of another sudden attack.
That concern was reflected in comments from the National Pancreas Foundation, which described the availability of TRYNGOLZA as an important new option for a community that has long needed better ways to reduce pancreatitis risk. For advocacy groups, the approval also highlights the need to improve recognition of sHTG as a serious metabolic disorder rather than a laboratory abnormality that can simply be monitored without urgent intervention.
Strategic Implications for the Lipid and Cardiometabolic Market
From a commercial standpoint, the approval opens a much larger market than Ionis’ earlier rare-disease indication in FCS. In materials tied to the sHTG program, the company has cited more than 3 million people in the U.S. living with severe hypertriglyceridemia, including roughly 1 million considered high-risk because of very high triglycerides or a prior history of pancreatitis. Not all of those patients will be immediate candidates for a branded injectable therapy, but the addressable population is nevertheless substantially broader than the FCS market and gives Ionis a meaningful opportunity to establish a presence in cardiometabolic medicine. (Ionis Pharmaceuticals, Inc.)
The approval also comes at a time when the biotech industry is paying close attention to the convergence of RNA-targeted medicines and cardiometabolic disease, an area historically dominated by small molecules and antibodies. By securing a label that explicitly includes reduction of pancreatitis risk, Ionis has differentiated TRYNGOLZA from more conventional triglyceride-lowering agents and may have created a platform for future expansion in related lipid disorders.
A Defining Milestone for Patients and for Ionis
Ultimately, the FDA approval of TRYNGOLZA for severe hypertriglyceridemia represents a significant advance on two fronts. For patients, it introduces a new treatment option that appears capable of delivering deep triglyceride lowering while also addressing the complication that matters most in this disease: acute pancreatitis. For Ionis, it marks a transition from a company known primarily for rare disease innovation into one seeking a larger role in prevalent metabolic disorders.
Whether TRYNGOLZA becomes a major commercial success will depend on physician adoption, payer access, and how effectively Ionis can translate its clinical data into real-world use. But from a scientific and regulatory standpoint, the approval is already a milestone: it is the first therapy in severe hypertriglyceridemia with evidence strong enough for the FDA to recognize both triglyceride reduction and pancreatitis-risk reduction on the label, giving a long-overlooked patient population a new option at a moment when better control of the disease can make a profound difference.
About the CORE and CORE2 Studies
CORE (NCT05079919; n=617) and CORE2 (NCT05552326; n=446), conducted with The TIMI Study Group, are Phase 3 global, multicenter, randomized, double-blind, placebo-controlled trials investigating the safety and efficacy of olezarsen for severe hypertriglyceridemia (sHTG). Participants aged 18 and older with triglyceride levels ≥500 mg/dL were enrolled.
Participants were required to be on standard of care therapies for elevated triglycerides. At baseline, 47% and 37% of participants had fasting triglycerides ≥880 mg/dL in CORE and CORE2, respectively. Participants were randomized to receive 50 mg or 80 mg of olezarsen or placebo every four weeks via subcutaneous injection for 12 months.
The CORE and CORE2 studies met the primary endpoint, with both 50 mg and 80 mg monthly TRYNGOLZA doses. TRYNGOLZA demonstrated a statistically significant reduction in fasting triglycerides of 49%-63% (50 mg) and 55%-72% (80 mg) compared to placebo at six months. Additionally, TRYNGOLZA demonstrated a statistically significant 91% (50 mg) and 76% (80 mg) reduction in acute pancreatitis events at 12 months, with a pooled reduction of 85%.
About Severe Hypertriglyceridemia
Severe hypertriglyceridemia (sHTG) is defined by very high triglycerides (≥500 mg/dL) and characterized by an increased risk of acute pancreatitis and other serious health complications. Considered a medical emergency, acute pancreatitis causes debilitating abdominal pain that often requires prolonged hospitalization, can lead to permanent organ damage and can become life-threatening. Preventing the first attack is key. In people with a history of acute pancreatitis episodes, the risk of future attacks is even greater.
Current standard of care therapies for sHTG and lifestyle modifications (such as diet and exercise) do not sufficiently or consistently lower triglyceride levels or reduce the risks of sHTG in all patients. More than 3 million people are living with sHTG in the U.S., including approximately 1 million who are considered high risk. High-risk sHTG includes those with triglycerides ≥880 mg/dL or triglycerides ≥500 mg/dL and a history of acute pancreatitis or other comorbidities.
About TRYNGOLZA® (olezarsen)
TRYNGOLZA® (olezarsen) is an RNA-targeted therapy designed to lower the body’s production of apoC-III, a protein produced in the liver that regulates triglyceride metabolism in the blood. TRYNGOLZA is approved in the United States as an adjunct to diet to reduce triglycerides (TG) and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG greater than or equal to 500 mg/dL). TRYNGOLZA is also approved in the United States, European Union and other countries for adults with familial chylomicronemia syndrome (FCS), a rare form of sHTG. Visit TRYNGOLZA.com for more information.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.
